NCT02971293View on ClinicalTrials.gov

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

August 18, 2017

Study Completion Date

August 18, 2017

Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
DRUG

AZD8871 100 µg

The subjects will receive one dose of AZD8871 100 µg single dose DPI.

DRUG

AZD8871 600 µg

The subjects will receive AZD8871, 600 µg single dose DPI.

DRUG

Placebo

The subject will receive Placebo single dose DPI.

Trial Locations (2)

14050

Research Site, Berlin

M23 9QZ

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT02971293 - Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871 | Biotech Hunter | Biotech Hunter